Esomeprazole Magnesium
Product Images NDC 68071-2649

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 68071-2649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2649 9)

Label for Esomeprazole Magnesium 40 mg capsules by NuCare Pharmaceuticals, Inc. The label states a quantity of 90 delayed-release capsules and includes product and barcode information. It also contains warnings to keep out of reach of children, storage instructions at controlled temperature, manufacturer details from Hetero Labs Limited, and a note to see the manufacturer's label for full ingredients.*

FDA Label Image

Esomeprazolemagnesiumfigure1 (Esomeprazolemagnesiumfigure1)

Chemical structure of Esomeprazole Magnesium showing the molecular arrangement including methoxy groups, nitrogen atoms, sulfur, and magnesium ion associated with three water molecules (Mg2+ 3H2O). The diagram depicts two repeating units of the esomeprazole molecule complexed with magnesium and water components.*

FDA Label Image

Esmoprazolemagnesiumfigure2 (Esomeprazolemagnesiumfigure2)

A line graph showing percent maintained over months for Esomeprazole Magnesium Delayed-Release Capsules 40 mg, 20 mg, and 10 mg, compared to a placebo. The x-axis represents time in months, while the y-axis represents percent maintained, depicting comparative performance among dosages and placebo over a 6-month period.*

FDA Label Image

Esmoprazolemagnesiumfigure3 (Esomeprazolemagnesiumfigure3)

A line graph showing percent maintained over 6 months for Esomeprazole Magnesium delayed-release capsules in 40 mg and 10 mg doses compared to placebo. The y-axis represents percent maintained, and the x-axis denotes time in months. The graph includes four trend lines indicating different treatment groups.*

FDA Label Image

Esomeprazolemagnesiumfigure4 (Esomeprazolemagnesiumfigure4)

A line graph showing the percentage of patients symptom-free over a 28-day diary period. It compares Esomeprazole Magnesium Delayed-Release Capsules at 40 mg and 20 mg doses, as well as a placebo group. The x-axis represents diary days from 0 to 28, and the y-axis shows the percent of patients symptom-free from 0% to 100%, with both Esomeprazole doses showing higher symptom-free percentages compared to placebo throughout the period.*

FDA Label Image

Esomeprazolemagnesiumfigure5 (Esomeprazolemagnesiumfigure5)

A line graph comparing the percentage of patients symptom-free over 28 diary days for Esomeprazole Magnesium Delayed-Release Capsules 20 mg versus placebo. The y-axis shows the percent of patients symptom-free, and the x-axis shows diary days from 0 to 28. Three data series are plotted: two for Esomeprazole Magnesium Delayed-Release Capsules and one for placebo, showing an increasing trend for the active drug groups compared to placebo.*

FDA Label Image

Camber (Camber)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.